How Long Does It Take for Zepbound to Work? A Week-by-Week Timeline From the Trials

How long does it take for Zepbound to work? A week-by-week timeline from the SURMOUNT trials: the first shot, when appetite changes, weight loss at weeks 8, 12 and 72, sleep apnea results, and what to eat meanwhile.

Published by womensglp1guide.com
Woman at a sunny kitchen table marking a paper wall calendar with a pencil, with a capped white injection pen and a glass of water on the table
Woman at a sunny kitchen table marking a paper wall calendar with a pencil, with a capped white injection pen and a glass of water on the table

How long does it take for Zepbound to work? Zepbound (tirzepatide) peaks in the blood about a day after a shot and reaches a steady level after 4 weekly doses, but weight loss builds over months [1]. In SURMOUNT-1 analyses, most people had lost 5% or more by week 8 to 12 [3][4]. At 72 weeks, average loss was 15.0% to 20.9% in adults without type 2 diabetes and 12.8% to 14.7% with it [1].

Most nausea, vomiting, and diarrhea in the trials also happened in these dose-increase weeks, as our page on Zepbound side effects explains. In this article:

  • The first week and when appetite changes
  • Weight loss at weeks 8, 12, 24, 72, and 88
  • Sleep apnea, women, and slow starters

Every timeline here comes from the FDA label and published trials, not anecdotes.

Table of Contents

How Long Does It Take for Zepbound to Work? The Short Answer

Zepbound reaches its peak blood level about a day after the first shot, while weight loss takes weeks to show and months to build [1][3][4].

Zepbound timeline from the first shot to week 88 (FDA label and SURMOUNT trials)
Time since first shot What the data show Source
8 to 72 hours Peak blood level after each shot (median 24 hours) Label 12.3 [1]
Week 1 Slowing of stomach emptying is largest after the first dose, then lessens Label 12.2 [1]
Week 4 Steady blood level; the 2.5 mg starter dose ends and 5 mg begins Label 2.1, 12.3 [1]
Week 8 62.1% of SURMOUNT-1 participants had lost 5% or more Kokkinos 2026 [4]
Week 12 82% of adherent SURMOUNT-1 participants had lost 5% or more Ard 2025 [3]
Week 20 Trial dose escalation ends at the latest Label 14.1 [1]
Week 24 70% of the week 12 slow starters had reached 5% Ard 2025 [3]
Week 72 Average loss 15.0% to 20.9% (no diabetes) Label Table 2 [1]
Week 88 25.3% average loss from week 0 in people who stayed on treatment after a 36-week lead-in SURMOUNT-4 [6]

These are trial averages and group shares (first shot = week 0), not a forecast for you [1][3].

Illustration of a winding path with five milestone markers showing a sunrise, a plate and fork, a moon and pillow, a walking shoe, and a flag

Zepbound in the First Week: Peak Blood Level and Stomach Emptying

In the first week, Zepbound reaches its highest blood level a median of 24 hours after the shot (range 8 to 72 hours) [1]. It also slows stomach emptying more than at any later point, but the label does not say when appetite changes start.

The label states that the stomach-emptying delay "is largest after the first dose" and fades over time [1]. A slower stomach can bring early fullness. Most nausea, vomiting, and diarrhea in the trials happened during dose escalation and decreased over time [1].

For warning signs and when to call your doctor, see our page on Zepbound side effects.

Tirzepatide has a half-life of about 5 days, which fits the once-weekly schedule [1]. The Medication Guide says you can inject at any time of the day [2].

When Does Zepbound Suppress Appetite?

Tirzepatide, the medicine in Zepbound, lowered food intake by week 3 in a small trial, but we found no study that measured appetite in the first days after the first dose. The label says tirzepatide "decreases calorie intake" and that the effect is "likely mediated by affecting appetite," without giving an onset time [1].

The earliest measured data we found come from two small trials:

  • Week 3. In a randomized 6-week trial of 114 adults without diabetes, energy intake at a test lunch was 524.6 kcal lower with tirzepatide than with placebo. The trial also found less reported hunger and fewer food cravings with tirzepatide [9].
  • Week 8. In adults with type 2 diabetes, mostly men, the tirzepatide 15 mg group cut its buffet lunch intake by 185.3 kcal more than the placebo group [8].

Both studies were small, used one test meal, and ran with manufacturer funding. They suggest intake can fall within weeks, not how much any one person will eat. People on GLP-1 medicines often describe this as quieter "food noise"; our article on food noise explains what studies show.

Why the First Month on Zepbound Is a Starter Phase

The first month on Zepbound is a starter phase. Everyone begins at 2.5 mg once weekly for 4 weeks, and the label says this dose "is for treatment initiation and is not approved as a maintenance dosage" [1]. Blood levels reach a steady state only after those 4 weekly doses [1].

The dose then goes to 5 mg, and the label allows further 2.5 mg steps after at least 4 weeks on the current dose, to lower the risk of stomach side effects [1]. Counting the first dose as week 0, the earliest possible pace reaches 5 mg at week 4, 10 mg at week 12, and 15 mg at week 20. That is label arithmetic, not a plan, and it matches SURMOUNT-1 [3]. The label lists 5, 10, and 15 mg as maintenance doses for weight, chosen by your prescriber based on "treatment response and tolerability" [1]. Our tirzepatide dosage chart shows the full schedule.

Missed a dose? The label says to take it within 4 days (96 hours) or skip it, and never take 2 doses within 3 days (72 hours) [1][2].

When Do You Start Losing Weight on Zepbound? Weeks 8, 12, and 24

In SURMOUNT-1 analyses, most participants on Zepbound had lost at least 5% of their weight within the first 2 to 3 months [3][4].

  • Week 8. By week 8, every participant had taken 5 mg for 4 weeks. In SURMOUNT-1 (no diabetes), 62.1% had lost 5% or more; in SURMOUNT-2 (type 2 diabetes), 40.6% had [4].
  • Week 12. Among 1,545 SURMOUNT-1 participants who took at least 75% of their doses, 82% had lost 5% or more, and 18% had not [3].
  • Week 24. Of those slow starters, 70% reached 5% by week 24 and 90% by week 72. The ones who got there took 24.8 weeks on average [3].

Early responders lost more on average, but slow starters still lost meaningful weight: in SURMOUNT-1, week 12 slow starters averaged 11.0% at week 72, compared with 22.5% for early responders [3]. In the week 8 analysis, stomach side effects followed a similar pattern in early and later responders, and the authors say they should not be used to "predict" response [4].

Both analyses are post hoc, meaning they were run after the trials ended. Eli Lilly, the maker of Zepbound, funded them, and they include only people who stayed on treatment [3][4]. They describe groups, not a prediction for you.

Myths About Week-by-Week Percentages

Many websites quote a fixed average loss for week 4 or week 12, or promise "25% in a year." We found no primary source for either figure. The closest figure to 25% is 25.3% at week 88 in SURMOUNT-4, only for people who finished a 36-week lead-in and stayed on treatment [6]. Week 72 is not a proven maximum either; it is when SURMOUNT-1 measured its main result [1].

How Much Weight Zepbound Users Lost by Week 72 and Beyond

By week 72, adults on Zepbound without diabetes lost 15.0% to 20.9% of their body weight on average, depending on dose, compared with 3.1% on placebo [1][5]. Adults with type 2 diabetes lost 12.8% to 14.7%, compared with 3.2% on placebo [1].

Does Zepbound work? For most trial participants, yes: 85.1% to 90.9% of people on Zepbound in SURMOUNT-1 lost at least 5% by week 72, compared with 34.5% on placebo [1].

Zepbound weight loss at week 72 by dose (FDA label Table 2, SURMOUNT-1 and SURMOUNT-2)
Group Average change Lost 5% or more Lost 10% or more Lost 15% or more Lost 20% or more
SURMOUNT-1 placebo -3.1% 34.5% 18.8% 8.8% 3.1%
SURMOUNT-1, 5 mg -15.0% 85.1% 68.5% 48.0% 30.0%
SURMOUNT-1, 10 mg -19.5% 88.9% 78.1% 66.6% 50.1%
SURMOUNT-1, 15 mg -20.9% 90.9% 83.5% 70.6% 56.7%
SURMOUNT-2 placebo (type 2 diabetes) -3.2% 32.5% 9.5% 2.7% 1.0%
SURMOUNT-2, 10 mg -12.8% 79.2% 60.5% 39.7% 21.5%
SURMOUNT-2, 15 mg -14.7% 82.8% 64.8% 48.0% 30.8%

Source: Zepbound Prescribing Information, Table 2, intention-to-treat analysis [1].

You can also see how the 72-week results compare with Wegovy.

In SURMOUNT-4, people who lost a mean 20.9% in a 36-week lead-in and kept taking tirzepatide reached 25.3% from week 0 at week 88, while those switched to placebo regained 14.0% [6]. In SURMOUNT-1 participants with prediabetes, loss at 3 years (week 176) was 12.3% to 19.7%, vs 1.3% on placebo [10].

What to Eat While Zepbound Starts Working

While Zepbound starts working, a reduced-calorie diet and regular activity match how the drug was tested. In SURMOUNT-1 and SURMOUNT-2, participants got instruction on a diet of about 500 kcal a day below their needs and counseling for at least 150 minutes of activity a week, from the first dose [1].

The label says tirzepatide lowers weight "with greater fat mass loss than lean mass loss" [1], yet in a SURMOUNT-1 substudy of 160 people, about a quarter of the weight lost was lean mass, the same share as with placebo [11]. A 2025 joint nutrition advisory pairs enough protein with strength training to help protect muscle [12]. See how much protein to eat on a GLP-1 and our GLP-1 workout at home. For high-protein recipes and meal ideas sized for a smaller appetite, see our guide.

Woman plating a lunch of salmon, beans, and leafy greens in a bright kitchen

Meal planning can help in the dose-increase weeks, when most nausea in the trials happened [1]. Plan a few simple protein-based meals and snacks ahead, so a low-appetite day does not become a skipped-meal day. Our GLP-1 meal plan shows one way to lay out a week, and our guide adds more recipes and meal ideas.

How Long Does Zepbound Take to Work for Sleep Apnea?

For obstructive sleep apnea (OSA), Zepbound's main results come from week 52 of two SURMOUNT-OSA trials, in which 469 adults with obesity had their dose raised over up to 20 weeks to 10 or 15 mg [1][7].

The trials measured the apnea-hypopnea index (AHI), the number of breathing pauses or shallow breaths per hour of sleep, at screening, week 20, and week 52 [7]. At week 52, in people not using PAP and people using PAP [1]:

  • AHI fell by 25.3 and 29.3 events per hour, vs 5.3 and 5.5 on placebo.
  • Remission or mild OSA without symptoms was reached by 42.2% and 50.2%, vs 15.9% and 14.3%.
  • Body weight fell 17.7% and 19.6%, vs 1.6% and 2.3%.

The label says the trials did not test when or whether people already using PAP should stop it [1]; ask your sleep clinician before changing PAP use. Whether a plan pays for Zepbound for sleep apnea is covered in what insurance covers Zepbound.

Zepbound Timeline for Women: What the Data Show

For women, the Zepbound timeline adds one date rule: birth control pills by mouth may not work as well while using Zepbound [1][2]. If you take the pill, the Medication Guide says your healthcare provider "may recommend another type of birth control for 4 weeks after you start ZEPBOUND and for 4 weeks after each increase in your dose" [2].

Early responders were more likely to be female; men made up 45% of week 12 slow starters vs 30% of early responders [3][4]. The Ard authors suggest lower drug exposure in men of the same weight, an untested hypothesis [3]. The label says weight loss occurred "irrespective of age, sex" and other factors [1]. Women made up 68% of SURMOUNT-1, 51% of SURMOUNT-2, and 71% of SURMOUNT-4 [1][6]. We found no separate week-by-week weight curve for women.

The Medication Guide says: "ZEPBOUND may harm your unborn baby. Tell your healthcare provider if you become pregnant while using ZEPBOUND." [2] The prescribing information tells prescribers to advise stopping Zepbound when a pregnancy is recognized [1]. The US label sets no waiting period before trying to conceive, so plan the timing with your prescriber.

What If You Are Not Losing Weight on Zepbound Yet?

A slow start on Zepbound is common and often temporary. In SURMOUNT-1, 18% of adherent participants had not lost 5% by week 12, yet 70% of them reached it by week 24 and 90% by week 72 [3].

Only 28 of the 1,545 adherent participants, about 2 in 100 by our arithmetic, never reached 5%; 4 of them had missed several doses in a row and restarted the escalation [3]. Some 2015 guidelines suggested stopping a weight loss medicine that fails to reach 5% within 12 weeks; the Ard authors conclude that continuing longer "may allow more patients to experience clinically meaningful weight reduction" [3].

The label tells prescribers to "consider treatment response and tolerability" when choosing the maintenance dose [1]. Questions to bring to your prescriber:

  • Have I missed doses, or restarted after a break?
  • Are side effects keeping me on a lower dose?
  • Could my other medicines or type 2 diabetes affect my results?
  • Am I following the diet and activity plan the trials used?

Never change your dose on your own. Stopping has a cost too: in SURMOUNT-4, people switched to placebo regained 14.0% of their body weight between weeks 36 and 88 [6]. Our page on the Zepbound maintenance dose covers what happens after you reach your goal.

Frequently Asked Questions

Does Zepbound work right away?

Zepbound peaks in the blood about a day after a shot, but weight loss takes weeks: 62.1% of SURMOUNT-1 participants had lost 5% by week 8 [1][4].

What should I expect in the first week on Zepbound?

You start on 2.5 mg, and stomach emptying slows most after the first shot, which can bring early fullness or nausea. The label does not say when appetite changes start [1].

Will I lose weight on 2.5 mg of Zepbound?

The label gives no weight result for 2.5 mg, a 4-week starter dose that "is not approved as a maintenance dosage" [1]. For low doses, see our page on microdosing tirzepatide.

How do I know if Zepbound is working?

Track your weight over weeks, not days. The trial analyses used a 5% loss as the marker, and your prescriber weighs response and tolerability together [1][3].

How long does one Zepbound shot last in the body?

The label gives tirzepatide a half-life of about 5 days, which fits once-weekly dosing [1].

Does a missed dose slow down Zepbound?

Possibly. In one analysis, 4 of the 28 people who never reached 5% had missed several doses in a row [3]. Take a missed dose within 4 days or skip it, and never take 2 doses within 3 days [1]. If you take too much, the Medication Guide says to "call your healthcare provider or Poison Help line at 1-800-222-1222 or go to the nearest hospital emergency room right away" [2].

Is the timeline the same for Mounjaro?

Mounjaro is the same medicine, tirzepatide, but it is approved for type 2 diabetes. Its label trials measured blood sugar (A1C) first, with weight change only as a secondary result [13]. See our Zepbound vs Mounjaro comparison.

What happens to the results if I stop Zepbound?

In SURMOUNT-4, people switched to placebo after 36 weeks regained 14.0% of their body weight by week 88; those who stayed on tirzepatide lost another 5.5% [6].

Key Takeaways

  • Fast in the blood, slow on the scale. Peak level in about a day, steady level at 4 weeks [1].
  • Weeks 8 to 12: most trial participants had lost 5% by then [3][4].
  • A slow start is common; most slow starters reached 5% by week 24 [3].
  • Results kept building to week 72, and to week 88 in people who stayed on treatment [1][6].
  • Safety rules stay the same. Never change your dose on your own. If you take too much, call your provider or Poison Help at 1-800-222-1222, or go to the nearest emergency room right away [2].

So how long does it take for Zepbound to work? Hours for blood levels, weeks for appetite, and months for most of the weight loss the trials measured.

References

  1. Zepbound (tirzepatide) Prescribing Information, revised 08/2026: Eli Lilly
  2. Zepbound Medication Guide, revised 08/2026: Eli Lilly
  3. Ard J et al. Weight reduction over time in tirzepatide-treated participants by early weight loss response: post hoc analysis in SURMOUNT-1. Diabetes Obes Metab, 2025;27(9):5064-5071
  4. Kokkinos A et al. Tirzepatide efficacy and tolerability according to early weight response: a post hoc analysis of the SURMOUNT-1 and SURMOUNT-2 trials. Diabetes Obes Metab, 2026;28(9):8367-8377
  5. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med, 2022;387(3):205-216
  6. Aronne LJ et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA, 2024;331(1):38-48
  7. Malhotra A et al. Tirzepatide for the treatment of obstructive sleep apnea and obesity (SURMOUNT-OSA). N Engl J Med, 2024;391(13):1193-1205
  8. Heise T et al. Tirzepatide reduces appetite, energy intake, and fat mass in people with type 2 diabetes. Diabetes Care, 2023;46(5):998-1004
  9. Martin CK et al. Tirzepatide on ingestive behavior in adults with overweight or obesity: a randomized 6-week phase 1 trial. Nat Med, 2025;31(9):3141-3150
  10. Jastreboff AM et al. Tirzepatide for obesity treatment and diabetes prevention. N Engl J Med, 2025;392(10):958-971
  11. Look M et al. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight. Diabetes Obes Metab, 2025;27(5):2720-2729
  12. Nutritional priorities to support GLP-1 therapy for obesity: joint advisory from ACLM, ASN, OMA, and TOS, 2025
  13. Mounjaro (tirzepatide) Prescribing Information, revised 08/2026: Eli Lilly

This article is for education only and is not medical advice. It summarizes the FDA label and published research, and it gives no personalized dosing advice. Talk to your prescriber about your treatment and your dose. Read our full medical disclaimer.

Back to blog